Literature DB >> 18622023

Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion.

Joaquim Calado1, Yves Sznajer, Daniel Metzger, Ana Rita, Marie C Hogan, Antonis Kattamis, Mauro Scharf, Velibor Tasic, Johann Greil, Florian Brinkert, Markus J Kemper, René Santer.   

Abstract

INTRODUCTION: Familial renal glucosuria (FRG) is a rare renal tubular disorder caused by mutations within the SLC5A2 gene. It is characterized by persistent glucosuria in the absence of hyperglycaemia and any other signs of generalized tubular dysfunction. In small series of patients previously reported, the molecular and phenotypic findings in FRG families, including first hints of extracellular volume depletion and activation of the renin-angiotensin-aldosterone system induced by natriuresis, have been described. We have now extended this analysis to another 21 consecutive cases from 17 pedigrees, including 11 cases with severe glucose excretion.
METHODS: Mutation analysis was performed by direct sequencing of the genomic coding segments of the SLC5A2 gene. In two cases with severe glucosuria, basal plasma renin activity and serum aldosterone concentrations were determined.
RESULTS: Within the 17 pedigrees, we have identified a total of 20 different SLC5A2 mutations. Fifteen have not been previously reported. In all glucosuric individuals tested, at least one SLC5A2 mutation could be identified. Heterozygous individuals were found to have only mild glucose excretion whereas homozygous or compound heterozygous patients had severe glucosuria, ranging from 10 to 86.5 g/1.73 m(2)/24 h. In two patients of the latter group, basal plasma renin activity and serum aldosterone concentration were determined and found to be raised to an average of 4.6-fold and 3.1-fold of the upper limit of the normal range, respectively. Discussion. The identification of at least one mutated allele in every affected individual in this cohort of 17 consecutively investigated families strongly suggests that genetic heterogeneity is not prevalent in FRG. Although 5 of the detected alleles have been described previously, 15 are novel, confirming that most mutations in FRG are private. Our finding of an activation of compensatory mechanisms for salt loss may warrant more detailed studies of long-term hormonal and metabolic imbalances in patients with FRG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622023     DOI: 10.1093/ndt/gfn386

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  29 in total

Review 1.  SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

Authors:  Ele Ferrannini; Anna Solini
Journal:  Nat Rev Endocrinol       Date:  2012-02-07       Impact factor: 43.330

2.  Familial renal glucosuria: a clinicogenetic study of 23 additional cases.

Authors:  HyunKyung Lee; Kyoung Hee Han; Hye Won Park; Jae Il Shin; Chan Jong Kim; Mee Kyung Namgung; Kee Hyuck Kim; Ja Wook Koo; Woo Young Chung; Dae-Yeol Lee; Su-Yung Kim; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2012-07       Impact factor: 3.714

Review 3.  SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys.

Authors:  Frederik H Verbrugge; Pieter Martens; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2017-08

4.  Glucosuria Is Not Always Due to Diabetes.

Authors:  Meghan Lewis; Bhagwan Dass
Journal:  Fed Pract       Date:  2021-02

5.  SGLT2 mediates glucose reabsorption in the early proximal tubule.

Authors:  Volker Vallon; Kenneth A Platt; Robyn Cunard; Jana Schroth; Jean Whaley; Scott C Thomson; Hermann Koepsell; Timo Rieg
Journal:  J Am Soc Nephrol       Date:  2010-07-08       Impact factor: 10.121

6.  A novel sodium-glucose co-transporter 2 gene (SGLT2) mutation contributes to the abnormal expression of SGLT2 in renal tissues in familial renal glucosuria.

Authors:  Lei Yu; Ping Hou; Ji-Cheng Lv; Guo-Ping Liu; Hong Zhang
Journal:  Int Urol Nephrol       Date:  2014-06-08       Impact factor: 2.370

7.  Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients.

Authors:  Lei Yu; Ji-Cheng Lv; Xu-jie Zhou; Li Zhu; Ping Hou; Hong Zhang
Journal:  Hum Genet       Date:  2010-12-17       Impact factor: 4.132

8.  Structural basis of inhibition of the human SGLT2-MAP17 glucose transporter.

Authors:  Yange Niu; Rui Liu; Chengcheng Guan; Yuan Zhang; Zhixing Chen; Stefan Hoerer; Herbert Nar; Lei Chen
Journal:  Nature       Date:  2021-12-08       Impact factor: 49.962

9.  SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.

Authors:  Michael J Jurczak; Hui-Young Lee; Andreas L Birkenfeld; Francois R Jornayvaz; David W Frederick; Rebecca L Pongratz; Xiaoxian Zhao; Gilbert W Moeckel; Varman T Samuel; Jean M Whaley; Gerald I Shulman; Richard G Kibbey
Journal:  Diabetes       Date:  2011-03       Impact factor: 9.461

Review 10.  The Use of Genomics to Drive Kidney Disease Drug Discovery and Development.

Authors:  Dermot F Reilly; Matthew D Breyer
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-19       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.